{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:15:33Z","timestamp":1792084533233,"version":"4.4.0"},"reference-count":11,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1454_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Managing acute gout attacks in renal failure patients on peritoneal dialysis (PD) is challenging. We report a unique case of a PD patient with recurrent pulmonary infections, heart failure, and severe anemia, who presented with refractory gout attacks successfully treated with the IL-1\u03b2 monoclonal antibody Firsekibart.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1454_abs_002\">\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 52-year-old female PD patient experienced recurrent swelling and pain in limb joints for one year, with acute exacerbation for three days. Laboratory tests showed serum uric acid (UA) 627\u202f\u03bcmol\/L and C-reactive protein (CRP) 16.6\u202fmg\/L. Conventional treatments with nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids were ineffective. Given the patient\u2019s high inflammatory state and multiple comorbidities, Firsekibart (200\u202fmg) was administered. Joint pain and swelling significantly improved within 24\u202fh. The Visual Analogue Scale (VAS) score decreased from 5 to 1 within 72\u202fh, and CRP dropped from 16.6\u202fmg\/L to 6.5\u202fmg\/L at day 3. UA decreased from 485\u202f\u03bcmol\/L to 388.9\u202f\u03bcmol\/L at day 7. At three-month follow-up, the patient remained free of gout recurrence, with VAS 1, CRP 7.8\u202fmg\/L, and UA 393\u202f\u03bcmol\/L. At the last 7-month telephone follow-up she reported no further acute gout attacks, though mild joint swelling persisted. No injection site reactions, hypersensitivity, or infectious complications were observed throughout the entire follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1454_abs_003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IL-1\u03b2 blockade Firsekibart may represent a safe and effective option for managing acute gout attacks in high-risk ESRD patients on PD with multiple comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1454","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:58:41Z","timestamp":1780405121000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute gout attack in a peritoneal dialysis patient treated with Firsekibart: a case report"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2996-9891","authenticated-orcid":false,"given":"Wenqian","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Nephrology , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1296-3252","authenticated-orcid":false,"given":"Lijie","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Nephrology , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1651-335X","authenticated-orcid":false,"given":"Hanyu","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Nephrology , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6768-0701","authenticated-orcid":false,"given":"Nan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-2511","authenticated-orcid":false,"given":"Shu","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of Nephrology , Shanghai General Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060212583531690_j_med-2026-1454_ref_001","doi-asserted-by":"crossref","unstructured":"Chen, Z, Lin, Y, Wang, J, Yao, K, Xie, Y, Chen, X, et al.. Relationship between compound \u03b1-ketoacid and microinflammation in patients with chronic kidney disease. Curr Pharm Des 2024;30:589\u201396. https:\/\/doi.org\/10.2174\/0113816128291248240131102709.","DOI":"10.2174\/0113816128291248240131102709"},{"key":"2026060212583531690_j_med-2026-1454_ref_002","doi-asserted-by":"crossref","unstructured":"McCarty, KL, Gaffo, AL, Diaz-Torne, C. Gout therapy updated. Ther Adv Musculoskelet Dis 2025;17:1759720X251384584. https:\/\/doi.org\/10.1177\/1759720X251384584.","DOI":"10.1177\/1759720X251384584"},{"key":"2026060212583531690_j_med-2026-1454_ref_003","doi-asserted-by":"crossref","unstructured":"Cronstein, BN, Sunkureddi, P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J\u00a0Clin Rheumatol 2013;19:19\u201329. https:\/\/doi.org\/10.1097\/RHU.0b013e31827d8790.","DOI":"10.1097\/RHU.0b013e31827d8790"},{"key":"2026060212583531690_j_med-2026-1454_ref_004","doi-asserted-by":"crossref","unstructured":"Pisaniello, HL, Fisher, MC, Farquhar, H, Vargas-Santos, AB, Hill, CL, Stamp, LK, et al.. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a gout, hyperuricemia and crystal-associated disease network (G-CAN)-initiated literature review. Arthritis Res Ther 2021;23:130. https:\/\/doi.org\/10.1186\/s13075-021-02416-y.","DOI":"10.1186\/s13075-021-02416-y"},{"key":"2026060212583531690_j_med-2026-1454_ref_005","doi-asserted-by":"crossref","unstructured":"Xue, Y, Chu, T, Hu, J, Gou, W, Zhang, N, Li, J, et al.. Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: a randomized phase 3 trial. Innovation 2025;6:101015. https:\/\/doi.org\/10.1016\/j.xinn.2025.101015.","DOI":"10.1016\/j.xinn.2025.101015"},{"key":"2026060212583531690_j_med-2026-1454_ref_006","doi-asserted-by":"crossref","unstructured":"Jing, J, Kielstein, JT, Schultheiss, UT, Sitter, T, Titze, SI, Schaeffner, ES, et al.. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German chronic kidney disease (GCKD) study. Nephrol Dial Transplant 2015;30:613\u201321. https:\/\/doi.org\/10.1093\/ndt\/gfu352.","DOI":"10.1093\/ndt\/gfu352"},{"key":"2026060212583531690_j_med-2026-1454_ref_007","doi-asserted-by":"crossref","unstructured":"Liang, J, Jiang, Y, Huang, Y, Song, W, Li, X, Huang, Y, et al.. Comorbidities and factors influencing frequent gout attacks in patients with gout: a cross-sectional study. Clin Rheumatol 2021;40:2873\u201380. https:\/\/doi.org\/10.1007\/s10067-021-05595-w.","DOI":"10.1007\/s10067-021-05595-w"},{"key":"2026060212583531690_j_med-2026-1454_ref_008","doi-asserted-by":"crossref","unstructured":"Jung, I, Lee, DY, Chung, SM, Yoon, JS, Won, KC, Kwon, HS, et al.. Impact of chronic kidney disease and gout on end-stage renal disease in type 2 diabetes: population-based cohort study. Endocrinol Metab 2024;39:748\u201357. https:\/\/doi.org\/10.3803\/EnM.2024.2020.","DOI":"10.3803\/EnM.2024.2020"},{"key":"2026060212583531690_j_med-2026-1454_ref_009","doi-asserted-by":"crossref","unstructured":"Loustau, C, Rosine, N, Forien, M, Ottaviani, S, Juge, PA, Paris, JF, et al.. Effectiveness and safety of anakinra in gout patients with stage 4\u20135 chronic kidney disease or kidney transplantation: a multicentre, retrospective study. Jt Bone Spine 2018;85:755\u201360. https:\/\/doi.org\/10.1016\/j.jbspin.2018.03.015.","DOI":"10.1016\/j.jbspin.2018.03.015"},{"key":"2026060212583531690_j_med-2026-1454_ref_010","unstructured":"Chinese Preventive Medicine Association, Rheumatology Prevention Committee. Guidelines for anti-inflammatory treatment of gout (2025 edition). Chin J Rheumatol 2025;29:897\u2013922. Chinese."},{"key":"2026060212583531690_j_med-2026-1454_ref_011","doi-asserted-by":"crossref","unstructured":"Yu, Y, Xue, Y, Hu, J, Wang, C, Zhang, Y, Li, Z, et al.. Firsekibart as a prophylactic treatment for acute gout flare in participants initiating urate-lowering therapy: a phase 2, randomized, open-label, multicenter, active-controlled trial. ACR Open Rheumatol 2025;7:e70111. https:\/\/doi.org\/10.1002\/acr2.70111.","DOI":"10.1002\/acr2.70111"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1454\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:58:46Z","timestamp":1780405126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1454\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1454"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1454","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261454"}}